The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.90
Bid: 29.10
Ask: 30.70
Change: 0.10 (0.34%)
Spread: 1.60 (5.498%)
Open: 29.80
High: 0.00
Low: 0.00
Prev. Close: 29.80
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Placing

2 Jun 2016 15:44

RNS Number : 0799A
EKF Diagnostics Holdings PLC
02 June 2016
 

2 June 2016

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Results of Placing

 

EKF Diagnostics Holdings plc (AIM: EKF) announces the successful completion of the Placing announced this morning. A total of 42,205,707 Placing Shares have been placed at a price of 11.25 pence per Placing Share. The Placing will raise gross proceeds of approximately £4.75 million.

 

The Placing, conducted by Panmure Gordon as Nominated Adviser and Corporate Broker, is conditional, inter alia, on Admission. The Placing Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares.

 

Application will be made to the London Stock Exchange for admission to trading of 42,205,707 Placing Shares on AIM ("Admission"). It is expected that Admission will take place at 8.00 a.m. on 7 June 2016 (at which time the Placing will become unconditional) and that dealings in the Placing Shares on AIM will commence at the same time.

 

Director dealings

 

The Company has been notified that North Atlantic Smaller Companies Investment Trust PLC ("NAIT") and Oryx International Growth Fund Limited ("Oryx") participated in the Placing as detailed below. Harwood Capital LLP ("Harwood") is investment manager and investment adviser to NAIT and Oryx respectively. Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood. Christopher Mills is also a director of Oryx and NAIT. He holds 2.16 per cent. of the shares in Oryx in his own name as well as a further 46.44 per cent. of the shares in Oryx via his 25.06 per cent. shareholding in NAIT.

 

Entity

Number of Placing Shares acquired pursuant to the terms of the Placing

Resulting holding post Admission

% of enlarged issued voting share capital

Oryx

4,650,000

40,000,000

8.62%

NAIT

16,297,656

64,947,656

13.99%

Total

20,947,656

104,947,656

22.61%

 

 

 

The Company has also been notified today that certain other Directors of EKF have agreed to acquire Placing Shares pursuant to the terms of the Placing. The beneficial interests of the participating Directors will, on Admission, be as follows:

Director

Number of Placing Shares acquired pursuant to the terms of the Placing

Resulting holding post Admission

% of enlarged issued voting share capital

Julian Baines

133,333

1,855,288

0.40%

Adam Reynolds

88,889

3,318,613

0.71%

 

Defined terms used in this announcement have the same meaning as set out in the Placing announcement issued by the Company on 2 June 2016 unless otherwise stated.

 

Disclosure and Transparency Rules

 

EKF's enlarged issued share capital immediately following the issue of the Placing Shares will be 464,262,781 ordinary shares, with one vote per ordinary share held. The aforementioned figure of 464,262,781 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in interest in, the share capital of the Company under the Disclosure and Transparency Rules.

 

 

EKF Diagnostics Holdings plc

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Robert Naylor (Corporate Finance)

Paul Fincham (Corporate Finance)

Rupert Dearden (Sales)

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUPCQUPQGCP
Date   Source Headline
9th Aug 20187:00 amRNSDiaSpect Tm McKesson US distribution agreement
8th Aug 20184:09 pmRNSHolding(s) in Company
24th Jul 20188:45 amRNSUS distribution agreement for diabetes assay kit
19th Jul 20187:00 amRNSManufacturing partnership with Oragenics, Inc.
4th Jul 20183:15 pmRNSExploring funding options for Renalytix AI
7th Jun 20182:30 pmRNSHolding(s) in Company
1st Jun 201810:00 amRNSUpdate regarding Renalytix AI PLC
31st May 20187:00 amRNSLicence and collaboration agreement signed
8th May 20183:10 pmRNSResult of AGM
18th Apr 201810:36 amRNSPosting of AR and Accounts & Notice of AGM
9th Apr 20188:25 amRNSUS FDA approval for Diaspect Tm
21st Mar 20182:18 pmRNSHolding(s) in Company
14th Mar 20187:00 amRNSFinal Results
21st Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSTrading update
29th Dec 20177:00 amRNSTotal Voting Rights
21st Dec 20177:00 amRNSShare cancellation
1st Dec 20177:00 amRNSTotal Voting Rights
7th Nov 20173:07 pmRNSHolding(s) in Company
2nd Nov 20179:18 amRNSConfirmation of share cancellation
1st Nov 20177:00 amRNSTotal Voting Rights
27th Oct 20175:05 pmRNSHolding(s) in Company
3rd Oct 20173:44 pmRNSCancellation of escrow shares PDMR dealing/buyback
21st Sep 201710:16 amRNSHolding(s) in Company
11th Sep 20177:00 amRNSHalf-year Report
6th Sep 20171:41 pmRNSReduction of capital
31st Aug 20177:00 amRNSNotice of Results
10th Aug 20177:00 amRNSHolding(s) in Company
7th Aug 20179:45 amRNSHolding(s) in Company
27th Jul 201711:18 amRNSResult of General Meeting
19th Jul 20178:54 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSTrading update
26th Jun 20177:00 amRNSNotice of GM
26th Jun 20177:00 amRNSCancellation of share options
10th May 201711:45 amRNSResult of AGM
10th May 20177:00 amRNSTrading Update & Structure Update
18th Apr 201712:00 pmRNSAnnual Financial Report
4th Apr 201710:55 amRNSHolding(s) in Company
21st Mar 20171:47 pmRNSDirector/PDMR Shareholding
21st Mar 201712:04 pmRNSHolding(s) in Company
20th Mar 20177:00 amRNSUpdate
20th Mar 20177:00 amRNSFinal Results
2nd Mar 20177:00 amRNSNotice of Results
22nd Feb 20177:00 amRNSChange of Nominated Adviser and Broker
9th Jan 20177:00 amRNSTrading update
7th Nov 20167:00 amRNSTrading update
7th Oct 20167:00 amRNSTrading update
19th Sep 20167:00 amRNSAppointment of Joint Broker
13th Sep 20169:09 amRNSHolding(s) in Company
12th Sep 201610:24 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.